Skip to main content
. Author manuscript; available in PMC: 2017 Aug 21.
Published in final edited form as: Biomaterials. 2015 Dec 21;83:12–22. doi: 10.1016/j.biomaterials.2015.12.022

Fig. 2. Biocompatibility of DNAzyme-gold particles and in vitro knockdown of TNF-α in rat peritoneal macrophages.

Fig. 2

(A) Schematic showing the sequences used for Dz, iDz, and Dz-NS AuNP conjugates. Green indicates the mRNA sequence, underlined bases denotes the location of phosphodiester hydrolysis. The red base shows the location of the mutation that leads to inhibition of Dz catalytic function. (B) Plot showing the fold change in TNF-α levels in untreated and LPS-stimulated macrophages that were also treated with Lipofectamine® as well as NS-Dz AuNPs. TNF-α levels were measured using an ELISA kit at the 24 hour time point and were normalized to untreated LPS stimulated cells and reported as fold changes in TNF-α expression levels. Grouped data (mean ± SEM; n=3). (C) Plot of TNF-α expression levels when macrophages are treated with NS-Dz, i-Dz, and Dz AuNP conjugates at the 24 hour time point. Grouped data (mean ± SEM; n=6) (*p<0.05; **p<0.01; ***p<0.001; One-way ANOVA followed by Tukey' Multiple Comparison post-test).